U.S. FDA Approves Cyltezo® (adalimumab-adbm) as First Interchangeable Biosimilar with Humira®

/PRNewswire/ -- Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA)...

Related Keywords

United States ,American ,Martin Alan Menter ,Thomas Seck ,Boehringer Ingelheim Biopharma ,Regulatory Affairs At Boehringer Ingelheim ,Abbvie Biotechnology Ltd ,Boehringer Ingelheim Pharmaceuticals Inc ,Boehringer Ingelheim ,Drug Administration ,Boehringer Ingelheim Animal Health In Duluth ,Boehringer Ingelheim Corporation ,American Academy Of Dermatology ,Animal Health ,Boehringer Ingelheim Fremont Inc ,Biologics License Application ,Regulatory Affairs ,Baylor University Medical ,American Academy ,Biopharmaceutical Contract Manufacturing ,Abbvie Biotechnology ,Prescribing Information ,Human Pharma ,Biopharmaceutical Contract ,Ingelheim Pharmaceuticals ,Boehringer Ingelheim Animal Health ,Boehringer Ingelheim Fremont ,Corporate Social Responsibility ,